Skip to main content
Premium Trial:

Request an Annual Quote

Celera Extends License for Nanogen's MGB Technology for Dx Development

NEW YORK (GenomeWeb News) – Celera has extended an existing licensing agreement for Nanogen's Minor Groove Binder technology that will enable it to develop additional diagnostic products, Nanogen said today.
Celera originally licensed the MGB technology in 2004 from Epoch Biosciences to develop hepatitis C genotyping products for patient management, monitoring, and treatment. Nanogen acquired Epoch for $97 million later that year.
Under the expanded agreement, Celera will use the MGB technology to develop in vitro diagnostic products for cardiovascular and oncological applications, Nanogen said.
Nanogen said that Celera will provide an upfront license fee, milestone and anniversary fees throughout development, and a royalty on sales of the diagnostic products.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.